Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant protein technology, has introduced 4RISE™, an integrated wet-lab validation solution aimed at advancing AI-designed molecules from computational predictions to experimental evidence. The announcement, made via NEWMEDIAWIRE, highlights a growing need in the biotechnology industry: as AI generates protein candidates at unprecedented speed, experimental validation remains essential to determine whether they properly express, bind targets, and demonstrate desired biological properties.
4RISE™ is built around four core strengths—Rapid, In-Depth, Seamless, and Empirical. The Rapid component features XPressMAX™ cell-free protein synthesis (CFPS), which enables recombinant protein expression in approximately three hours, with success rates exceeding 99% in established workflows. Combined with more than 11,000 ready-to-use target proteins and high-throughput SPR/BLI analysis, applicable workflows can deliver AI-ready binding data in as little as three days. Structured experimental data and API access further support integration into downstream research and optimization workflows.
The In-Depth component goes beyond target binding and kinetic characterization to assess developability and biological function. More than 20 developability assays, alongside molecular and cell-based functional assays, help researchers evaluate candidate quality and biological activity. Seamless support is provided through complementary cell-free and mammalian expression platforms, extensive target coverage, and integrated validation from sequence screening to candidate evaluation. Empirical experience is backed by Sino Biological's established high-throughput platforms and collaborations with more than 50 AI companies, spanning diverse molecule types such as miniproteins, VHH, scFv, Fab, IgG, enzymes, and cytokines.
“AI-driven discovery requires more than computational predictions. Researchers need reliable experimental evidence to evaluate candidates and guide subsequent design decisions,” said Dr. Rob Burgess, Chief Business Officer at Sino Biological US. “4RISE™ combines rapid expression, extensive target resources, and in-depth validation to help researchers move faster and gain deeper insights.”
The launch matters because AI-driven protein design is transforming drug discovery, but without robust wet-lab validation, promising computational candidates can fail in later stages, wasting time and resources. By offering a streamlined path from AI design to experimental evidence, 4RISE™ could reduce bottlenecks in antibody and protein engineering, potentially accelerating therapeutic development. Sino Biological, which serves researchers in more than 90 countries, positions 4RISE™ as a bridge between computational innovation and practical application. More details are available on the company’s high-throughput wet-lab validation services page. As AI expands the possibilities of recombinant protein design, integrated validation solutions like 4RISE™ may become essential infrastructure for the biotech industry, helping ensure that AI-generated molecules can be reliably translated into real-world therapies and diagnostics.
